1. Christine M. Kornmeier
1
1520 Charlemont Dr. • Chesterfield, MO • 63017
314.602.5609 • kornmeier@att.net
http://www.linkedin.com/in/kornmeier
SUMMARY
Research & Development Biologist with broad expertise in the Life Sciences & Drug Discovery.
Proven ability to balance demands of multiple Stage Gate-managed project teams. Expert in assay
development & high throughput screening (HTS). Experienced training lead, mentor and expert
technical resource for collaborations, customer contact & maketing.
PROFESSIONAL EXPERIENCE
MilliporeSigma (A subsidiary of Merck KGaA, Darmstadt, Germany)
Sigma-Aldrich Corp. (Aquired by Merck KGaA, Darmstadt, Germany, 2015)
Senior R&D Scientist, 2011 – present: Protein Technologies & Assays Dept., St. Louis, MO
Sigma-Aldrich Catalog: Products Developed / Supported
• MSQC6 SILuTM
MAB K1 Stable-Isotope Labeled Universal Antibody Standard for Mass
Spectrometry, IgG1 kappa, human
• MSQC7 SILuTM
MAB K4 Stable-Isotope Labeled Universal Antibody Standard for Mass
Spectrometry, IgG4 kappa, human
• MS-SAFETM
Mass Spectrometry compatible protease & phosphatase inhibitor cocktail
• TruPAGETM
Precast Gels for SDS-PAGE
Key Contributions to R&D and Marketing Teams
• Developed high expression, growth & production stable isotope-labeled recombinant
antibodies in CHOZNTM
platform cell line.
• Lead Scientist for Marketing’s high level presentions & research proposals to Food Industry
customers seeking solutions in pathogen testing.
• Lead R&D expert for Marketing’s campaign “Protect Your Protein - Western Blot”; developed
in conjunction with Linus Group Consultants and IllustratedMan Video Productions.
• Sales force trainer for TruPAGE applications & troubleshooting; training videos; OEM
collaborations.
• HTS team multiplex bioassay screen (BioPlex) for cardiovascular disease biomarkers in
7500 plasma samples from the Framingham Multigenerational Study – Grants from NIH &
Boston University.
• Mentor (3 years) for Summer Intern Program in which undergraduate & gradulate level
Biology & Chemistry students are assigned defined research projects culminating in
company wide poster presentations.
Pfizer Inc. (Exited St. Louis R&D, 2010)
Pharmacia Corp. (Aquired by Pfizer Inc., 2003)
Monsanto Company (Aquired by Pharmacia & UpJohn, 2000)
G.D. Searle & Co. (Aquired by Monsanto Co. 1985)
Senior Scientist, 2003–2010: Inflammation Research Biology, St. Louis, MO
Research Scientist, 1999-2003: Arthritis & Inflammation Pharmacology, St. Louis MO
Research Associate 1991-1999: Discovery Pharmacology, St. Louis MO
Biologist 1988-1991: Molecular & Cellular Biology, St. Louis MO

2. Christine M. Kornmeier
2
Key Contributions to Project Teams
Selective Inhibitors of Inducible Nitric Oxide Synthase as osteoathritis anti-inflammatory therapeutic.
• Team member from project inception through clinical trials (SD-6010).
• Screened 2000 compound library through lead optimization & compound structure activity
relationships.
• Chromatography purification of NOS enzyme isoforms (native & recombinant);
• Enzyme & inhibitor kinetics assays.
• Developed & utilized a variety of assay platforms to identify iNOS expression in mammalian
cell lines & biomarkers of ostaeoarthritis disease in animal models and human biobank
samples: ELISA, Multiplex (Luminex/Bioplex, Mesoscale), AlphaScreen; FRET, Taqman,
radiolabled metabolic cell assays.
• Performed mitochondrial transporter assays to elucidate specific inhibitor toxicity issue.
• Developed unique spin trap nitrosylated protein detection method. Collaborated in
exploration of Gadolinium detection system for nitrosylated proteins.
• Profiled & curated anti-NOS isoform antibody library.
Selective inhibitors of Rho Kinase as potential therapeutic of Liver Fibrosis
• Analyzed ROCK1/2 phosphorylation signaling cascades in Jurkat cells.
• Developed In-Cell Western (LiCor) phosphokinase biomarker assay to screen 300
compound library for potent & selective inhibitors of ROCK2.
Selective Inhibitors of Hematopoietic Prostaglandin D Synthase as potential therapeutic in allergy &
respiratory inflammation.
• Adapted human peripheral blood mononuclear cells in radiolabeled assay from Incyte Corp.
to screen 2000 compound library for potent receptor antagonist. Project completed with
identification of lead compound.
Inhibition of Vascular Cell Adhesion Molecule (VCAM) as potential Cardiovascular Disease therapeutic.
• Cloned human VCAM; generated GST-fusion proteins in E. coli and stable cell lines;
produced anti-VCAM polyclonal antibodies, developed ELISA assay for detection of VCAM
in animal models of atherosclerosis.
Interleukin-3 Mimetics as potential Cancer Treatment Adjunctive Immunotherapy.
• Developed ELISA; HTS screen of hematopoetic mimetic libraries.
• Expression cloned hIL-3 receptor.
Washington University School of Medicine
Research Technician, 1986 – 1988; Pharmacology Dept., St. Louis, MO
Role of glycosylation on structure-function activity of glycoprotein hormones.
• Performed site directed mutagenesis of thyrotropin hormone for metabolic labeling structure
function studies in transient and stable transfected cell lines.
EDUCATION 1985, BA, Physics, Washington University, St. Louis, MO
Patents
1. SPI Docket # 01201: Metal Complexes as MRI Contrast Agents
that detect Nitric Oxide in Biological Samples. James Bashkin,
Claude Jones, William Neumann, Thomas Misko, Christine
Kornmeier, John Kotyk
2. SPI Docket # 01195: Methods of Detecting Nitric Oxide
Production in vivo. Claude Jones, James Bashkin, Thomas
Misko, Randall Rader, John Kotyk, William Neumann, Christine
Kornmeier
3. SPI Docket # 01195/2: Contrast Agents useful in Quantifying
Nitric Oxide. Claude Jones, James Bashkin, Thomas Misko,
Randall Rader, John Kotyk, William Neumann, Christine
Kornmeier
4. PCT Int. Appl. (2004), 32 pp WO 2004/002536. Methods and
contrast agents useful inquantifying nitric oxide.
Claude Jones, James Bashkin, Randall Rader, John Kotyk,
William Newmann, Thomas Misko, Christine Kornmeier,
(Pharmacia Corporation, USA)
5. PCT Int. Appl (2005) 11pp WO 2005081622. Method and
compositions for the detection of nitric oxide.
Mason Hughes, Christine Kornmeier, Thomas Misko, Barnett
Pitzele, (Pharmacia & UpjohnCompany LLC, USA)

3. Christine M. Kornmeier
3
Publications
1. Kornmeier, C.M. and Sutton, S.R., "Thermoluminescence
Dating Results for Ten Ceramics from Site 23BU10 in the Ozark
National Scenic Riverways," National Parks Service Report,
Midwest Archaeological Center, April 1885.
2. Kornmeier, C.M. and Sutton, S.R., "Ages corrected for Ambient
Activation: A Supplemental Report to Thermoluminescence
Dating Results for Ten Ceramics from Site 23BU10 in the Ozark
National Scenic Riverways," National Parks Service Report,
Midwest Archaeological Center, June 1985.
3. Sutton, S.R. and Kornmeier, C.M., "A Correction Procedure for
Ambient Activation in Predose Dating," Ancient TL Newsletter,
Vol.3, No.3, October 1985.
4. Matzuk, M.M., Kornmeier, C.M., Whitfield, G.K., Kourides, I.A.,
Boime, I., "The Glycoprotein Alpha-Subunit is Critical for
Secretion and Stability of the Human Thyrotropin Alpha-Subunit,"
Molecular Endocrinology, 2:95-100, (1988).
5. Ribbons, K.A., Zhang, X., Thompson, J.H., Greenberg, S.S.,
Moore, W.M., Kornmeier, C.M., Currie, M.G., Lerche, N.,
Blanchard, J., Clark, D.A., Miller, M.J.S., “Potential Role of Nitric
Oxide in a Chronic Model of Colitis in Rhesus Macaques,”
Gastroenterology, 108-000-000, (1995).
6. Moore, W.M., Webber, R.K., Fok, K.F., Jerome, G.M.,
Kornmeier, C.M., Tjoeng, F.S., Currie, M.G., “Inhibitors of Human
Nitric Oxide Synthase Isoforms with the Carbamidine Moiety as a
Common Structural Element,” Bioorganic & Medicinal Chemistry,
Vol. 4, No 9, pp 1559-1564, (1996).
7. Hagen, T.J., Bergmanis, A.A., Kramer, S.W., Fok, K.F.,
Schmelzer, A.E., Pitzele, B.S., Swenton, L., Jerome, G.M.,
Kornmeier, C.M., Moore, W.M., Branson, L.F., Connor, J.R.,
Manning, P.T., Currie, M.G., Hallinan, E.A., “2-Iminopyrrolidines
as Potent and Selective Inhibitors of Human Inducible
Nitric Oxide Synthase,” Journal of Medicinal Chemistry, Vol. 41,
No. 19, pp 3675-3683, (1998).
8. Hansen, D.W. Jr., Peterson, K.B., Trivedi M., Kramer, S.W.,
Webber, R.K., Tjoeng, F.S, Moore, W.M., Jerome, G.M.,
Kornmeier, C.M., Manning, P.T., Connor, J.R., Misko, T.P.,
Currie, M.G., Pitzele, B.S., “2-Iminohomopiperidinium Salts as
Selective Inhibitors of Inducible Nitric Oxide
Synthase,” Journal of Medicinal Chemistry, Apr 23; 41(9), pp
1361-1366, (1998).
9. Fretland, D.J., Widomski, D.L., Anglin, C.P., Moore, W.,
Jerome, G., Kornmeier, C., Connor, J., Branson, L., Wyatt, P.,
Manning, P., Toth, M., Webber, R.K., Hansen, D., Hallinan, E.A.,
Hagen, T., Bergmanis, A., Pitzele, B., Currie, M.G., “Specific
Inhibitors of Inducible Nitric Oxide Synthase:
Efficacy in a Rodent Model of Sepsis,” Inflammation Research,
Supplement 2, pp 796, (1999).
10. Mooreman, A.E., Metz, S., Toth, M.V., Moore, W.M., Jerome,
G., Kornmeier, C., Manning, P., Hansen, D.W., Jr., Pitzele, B.S.,
Webber, R.K., “Selective Heterocyclic Amidine Inhibitors of
Human Inducible Nitric Oxide Synthase,” Bioorganic & Medicinal
Chemistry Letters, 11, pp 2651-2653,
(2001).
11. Carron, C.P., Trujillo, J.I., Olson, K.L., Huang, W., Hamper,
B.C., Dice, T., Rohrer, D.C., Keifer, J.R., Moon, J.B., Schweitzer,
B.A., Blake, T.D., Turner, S.R., Woerndle, R., Case, B.L., Bono,
C.P., Dilworh, V.M., Funckes-Shippy, C.L., Hood, B.L., Jerome,
G.M., Kornmeier, C.M., Radabaugh, M.R., Williams, M.L.,
Wittwer, A.J., Wegner, C.D., Welsch, D.J., Abraham, W.M.,
Warren, C.J., Dowty, M.E., Hua, F., Zutshi, A., Yang, J.Z.,
Thorarensen, A., “Discovery of an Oral Potent Selective
Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS),”
ACS Medicinal Chemistry Letters 2010 May 13,; 1(2), 57-63
12. Trujillo, J.I., Kiefer, J.R., Huang, W.; Day, J.E., Moon, J,
Jerome, G.M., Bono, C.P., Kornmeier, C.M., Williams, M.L., Kuhn,
C., Rennie, G.R., Wynn, T.A., Carron, C.P., Thorarensen, A.,
“Investigation of the binding pocket of human hematopoietic
prostaglandin (PG) D2 synthase (hH-PGDS): a tale of two waters,
Bioorg Med Chem Letters, 2012 Jun 1; 22(11); 3795-9